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Following some time in research, I put down my pipettes to join Blood Cancer UK as a Policy Officer. Blood
Cancer UK is a medium-sized charity that funds research and provides information, support, and advocacy
to those affected by its namesake. The charity aims to put people affected by blood cancer at the centre of
its work. This is easy (and increasingly popular) to say, but harder to do. Recognising that our policy work
often lacked patient insight, I established a ‘Policy Panel’ (see Box 1). New to the acronym-dense policy world,
below are some of the lessons I learned setting up and managing the Panel, and advice1 for those considering a
similar group.
Box 1: About the Policy Panel
Composed of ∼20 individuals from across England with personal experience of blood cancer, the
Blood Cancer UK Policy Panel was established to provide insight and direction to the organisation’s
policy work, and to ensure its work to influence the health policy agenda reflects the community’s
priorities. In addition to providing ad hoc input to the charity’s work via telephone and email, Panel
members regularly participate in NHS, government, and parliamentary events to ensure blood cancer
is well represented, and that the issues affecting patients are understood by decision makers. Twice
a year, the group additionally meets in person (via videoconferencing at present due to COVID-19
restrictions) to explore pertinent blood cancer policy issues in detail.
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Descriptive, Not Prescriptive
Patient and Public Involvement (PPI) can de-
liver multiple benefits to organisations but is all
too often a poorly thought through ‘tick-box’ ex-
ercise. In designing your group, consider what
value PPI could add to your activities and work
backwards from there. Draft a clear Terms of
Reference (ToR) describing your group’s purpose,
what will be asked of members, and how you will
work together, etc. Once your group has been
established, communicate frequently, openly, and
in plain English.
That being said, be flexible where possible. In
drafting your ToR, you described in detail what
your group will and will not do – perhaps you
were a little too prescriptive? Your group is
composed of knowledgeable and passionate in-
1See final section ‘Disclaimer and Final Reflections’.
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dividuals. In policy, things move gradually, then
suddenly. When unexpected influencing oppor-
tunities arise, consider whether your group can
play a role in campaigning for change.
(Re)set Expectations
To the uninitiated, it’s clear that in a given char-
ity, the support team supports, the fundraising
team fundraises, and the policy team. . . does
something in Westminster? Policy is a nebulous
word. It is therefore important to set clear and
realistic expectations to your new group – explain
what policy is, what it can achieve, and the pace
it moves at.
Furthermore, often driven by a poor personal
experience with their treatment or care, many
applicants to your group will do so seeking to
campaign passionately for a particular change.
With limited capacity (and budget) it is impor-
tant that you are clear which issues your group
will focus on. This will manage expectations and
avoid potential later frustration.
Reflect Your Community
Health inequalities in the UK are multi-
dimensional and widening. It is therefore impor-
tant that your group is reflective of the community
it purports to represent in terms of age, gender,
ethnicity, and multiple other characteristics. Al-
though blood cancer affects all demographics, it
will surprise few in the charity sector that the
majority of initial applicants to the Blood Can-
cer UK Policy Panel were white, female, older,
and from the South East of England. To ensure
a more representative Panel, we actively sought
applicants from under-represented groups; work-
ing closely with cancer Clinical Nurse Specialists
‘on the wards’ and blood cancer organisations
primarily serving minority ethnic communities.
When arranging meetings, it is important to re-
member that while you will likely be travelling via
the Central Line and paid for the pleasure(!), your
group will be travelling from across the country –
voluntarily. Increase accessibility, particularly to
those less affluent or residing outside of London
by covering expenses in full.
Proper Prior Planning. . .
Meet regularly but never for the sake of meet-
ing. Consider what aspects of your work could
be furthered by having your group together for
an extended period of time (to provide insight to
your work; to sense-check your tentative policy
recommendations; to discuss an emerging issue?)
and format your meeting accordingly.
Always consider the needs of your group and their
‘user experience’. If performing work on a topic,
particularly where complicated or technical, con-
sider providing a briefing beforehand to ensure
everyone has a sufficient understanding to con-
tribute to a discussion. Remember that you are
working with real people with busy lives: give
dates well in advance as well as an agenda and an
abundance of practical details – not just where
to meet but how to get there as well.
Trust Your Group (But Also
Yourself)
Your group are experts by experience. You can
analyse all the NHS statistics available, but only
a patient can describe what their late diagno-
sis felt like. Frequently, the NHS, research cen-
tres, and similar organisations seek the ‘[insert-
disease-name-here]-perspective’ to inform their
work. What is typically being sought here is not
a PPE graduate with an encyclopaedic knowledge
of NICE guidance, but a genuine patient voice.
Through working together closely over time, your
professional recommendations will increasingly
mirror your group’s. Simultaneously, your indi-
vidual group members will become better able
to provide perspectives broader than their own,
and can attend events independently to represent
their wider community (additionally increasing
your reach and capacity).
However, you are the person being paid to anal-
yse the NHS statistics and who understands the
intricacies of the broader health policy landscape.
Allow your group to inform and influence your
policy recommendations (lobbyist, lobby thyself!)
but not to determine them for you. Although
admittedly tempting to accept recommendations
from your group members wholesale – especially
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when pushed for time or capacity – it is impor-
tant to objectively evaluate each recommenda-
tion; even if borne out of personal experience or
perfectly formatted to slot into a workshop or
ongoing inquiry.
Sell, Sell, Sell
Your group is wonderful – so talk about it pub-
licly and at every opportunity. The benefits are
two-fold: your organisation’s supporters will be
pleased to see the important work you are doing
in conjunction with members of their commu-
nity, and decision makers will be more likely to
proactively approach you with influencing oppor-
tunities due to your unique resource.
But also use your group to create new opportuni-
ties. For example, while you may have previously
found the minister unable to meet due to severe
diary pressures (read: you are one of N groups
seeking to introduce a subject to the medical
school curriculum), offering to meet with a repre-
sentative group of patients often results in time
being found. There is power in numbers and a
person’s story is almost always more captivating
than a cost-benefit analysis.
Disclaimer and Final Reflec-
tions
Patient and public involvement varies greatly be-
tween sectors and organisations. Above are my
personal reflections, written from the narrow per-
spective of someone new to policy, working in one
such sector, for one such organisation – ensure
that your group is appropriate for your organisa-
tion and the landscape in which it operates.
Measuring impact in policy is challenging – a lever
pulled in one area often brings about change in
another, months or even years later. Regard-
less of the metric applied, my team can point to
numerous successes: evidence submitted to par-
liamentary inquiries; new drugs available on the
NHS; meetings with government ministers. Many
of these achievements were aided by the Blood
Cancer UK Policy Panel; some were only made
possible by the group. My thanks to all members
for their engagement, hard work, and friendship.
© 2021 The Author. Published by the Cambridge
University Science & Policy Exchange under the
terms of the Creative Commons Attribution License
http://creativecommons.org/licenses/by/4.0/,
which permits unrestricted use, provided the original
author and source are credited.
Acknowledgements
The author would like to thank the Blood Cancer
UK Policy, Campaigns, and Engagement Team
(in particular Phil Reynolds and Christopher
Walden) as well as members of the Blood Cancer
UK Policy Panel.
About the Author
Dr. Ross P. Coron
(@Ross_Coron) is a
Science Policy Offi-
cer at the Depart-




work on genomics, regenerative medicine, and
rare disease. Prior to joining the Civil Service,
Ross was a Policy and Public Affairs Officer at the
medical research charity Blood Cancer UK and
has held several postdoctoral research positions in
the field of molecular and biochemical parasitol-
ogy. He can be contacted at rpcoron@gmail.com.
Conflict of interest The Author declares no
conflict of interest.
Cambridge Journal of Science & Policy, Vol 2 (2021), Issue 1 3
